Tag Archives: glioblastoma
Comprehensive genetic analysis of glioblastomas by The Cancer Genome Atlas (TCGA) has proposed a new classification based on genetic abnormalities. The characteristic genetic abnormalities identified in the TCGA are promising candidates for novel molecularly targeted therapies, and
Cancer immunotherapy utilizes the patient’s immune system to recognize and/or destroy tumors. The immune system has both positive activator/effector and negative inhibitory functions. Immune checkpoints are one such inhibitory function that can be overcome by immune checkpoint
Glioblastoma (GB) is the most frequent primary brain tumor in adults. The prognosis of GB is poor: median survival time is less than one year since the diagnosis and patients usually die within two years. Standard therapy,
Cancer is a multifactorial disease caused by the accumulation of “mistakes” in the production of proteins involved in the control of important cellular processes. These processes, such as cell division, cell growth and programmed cell death (i.e.
Glioblastoma remains one of the deadliest diseases faced by patients, with a median survival of less than 15 months. Therapeutic advancements in the field rely heavily on animal models, and the use of human brain tumor cells
Melatonin is well known as a treatment for jet lag, being naturally released by the brain when we close our eyes to go to sleep. However, recent research shows that melatonin is released by many, if not
Glioblastoma (GBM), the most common and aggressive primary brain tumor, is characterized by excessive growth and infiltration of the normal brain which prevents the complete surgical resection. These tumors also are refractory to standard treatment strategies, which